Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 9 Aug 2026

Will PRRT Control Your Carcinoid Syndrome Symptoms?

Carcinoid syndrome - flushing, diarrhea, and abdominal cramps driven by hormone-producing GEP-NETs - can persist even on somatostatin analogues. Research shows that PRRT using lutetium Lu-177 dotatate may reduce these hormone-driven symptoms alongside slowing tumour growth.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 9 Aug 2026
Will PRRT Control Your Carcinoid Syndrome Symptoms?

This article is for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) - specifically those living with carcinoid syndrome whose hormone symptoms are becoming harder to control. If your oncologist is discussing lutetium Lu-177 dotatate - the radioactive drug used in PRRT (peptide receptor radionuclide therapy) - as a next step, this page explains whether it can help your symptoms.

Direct answer: PRRT using lutetium Lu-177 dotatate may reduce flushing, diarrhea, and abdominal pain in patients with functional GEP-NETs - including those whose symptoms were not well controlled on somatostatin analogues alone. This benefit may come from the treatment slowing tumour growth.

What Is Carcinoid Syndrome - and What Makes a NET Functional?

Not all neuroendocrine tumours cause problems by releasing hormones. Those that do are called functional NETs. When a functional NET releases large amounts of serotonin and other substances into the bloodstream - usually after spreading to the liver - the result is carcinoid syndrome.

The main symptoms of carcinoid syndrome include:

  • Skin flushing - a sudden reddening or feeling of warmth in the face and upper chest
  • Watery diarrhea, sometimes urgent and frequent enough to disrupt sleep
  • Abdominal cramping and pain
  • Wheezing or shortness of breath
  • A fast or irregular heartbeat during flushing episodes

According to the Mayo Clinic, these symptoms are triggered by serotonin, histamine, and other substances released from carcinoid tumours. They tend to appear once the tumour has spread - particularly to the liver - because the liver can no longer break down these substances before they reach the rest of the body.

The Neuroendocrine Tumor Research Foundation (NETRF) notes that carcinoid syndrome can seriously affect daily life. The unpredictability of flushing episodes and urgent diarrhea can make ordinary activities feel unmanageable. Many patients describe the fatigue that follows a bad flushing episode as one of the most draining parts of their day.

Why Somatostatin Analogues Sometimes Stop Being Enough

For many patients with functional NETs, the first medical treatment for carcinoid syndrome is a class of drugs called somatostatin analogues (SSAs). The most widely used are octreotide LAR (long-acting release) and lanreotide. These drugs work by binding to somatostatin receptors on NET cells and slowing the secretion of the hormones that cause symptoms.

SSAs help a significant proportion of patients with carcinoid syndrome. But they do not work for everyone. In some patients, hormone control that was once adequate begins to break down. Flushing episodes return. Diarrhea becomes harder to manage even with dose adjustments. This is sometimes called refractory carcinoid syndrome - symptoms that persist despite SSA therapy.

When this happens, patients and their oncologists need to look at what comes next. PRRT is one of the options that guidelines recommend considering at this stage, particularly in patients whose tumours show somatostatin receptor expression on imaging.

How Lu-177 DOTATATE Targets the Same Receptors That Cause Your Symptoms

Lutetium Lu-177 dotatate works by attaching a radioactive particle - lutetium-177 - to a molecule called dotatate. Dotatate is structurally similar to somatostatin. It seeks out and binds to somatostatin receptors (specifically SSTR2) that are overexpressed on the surface of many GEP-NET cells.

These are the same receptors that SSAs target. The difference is that lutetium Lu-177 dotatate does not just suppress hormone release - it delivers targeted radiation directly into the cells carrying those receptors. The radiation damages and eventually kills the NET cells themselves, including those responsible for producing the serotonin and other substances that cause carcinoid syndrome.

This approach, using the tumour's own receptor to guide a radioactive payload, is called theranostics. You can read more about the mechanism on our page about how Lu-177 DOTATATE works by targeting somatostatin receptors. To receive PRRT, your tumour cells must express these receptors at a sufficient level - confirmed through a Ga-68 DOTATATE PET scan before treatment is offered.

What the Evidence Shows About Hormone Symptom Control During PRRT

The strongest clinical evidence comes from the NETTER-1 trial, a randomised phase 3 study comparing lutetium Lu-177 dotatate plus standard-dose octreotide LAR against high-dose octreotide LAR alone in patients with progressive midgut NETs. This trial formed the basis for the United States Food and Drug Administration approving lutetium Lu-177 dotatate (brand name Lutathera) for GEP-NETs, as reported by the National Cancer Institute.

The NETTER-1 data showed statistically significant reductions in abdominal pain, diarrhea, and flushing among patients treated with lutetium Lu-177 dotatate compared with those receiving high-dose octreotide LAR alone. A quality-of-life study from the trial, published in the Journal of Clinical Oncology, found that lutetium Lu-177 dotatate delayed health decline to a median of 28.8 months versus 6.1 months with standard treatment.

Research focused on refractory carcinoid syndrome adds to this picture. A clinical study published in Frontiers in Oncology examined PRRT in patients whose flushing and diarrhea were not adequately controlled on SSAs. The authors found that PRRT was associated with meaningful reductions in these hormone-driven symptoms and concluded that lutetium Lu-177 dotatate can be considered for symptomatic treatment of carcinoid syndrome that is insufficiently controlled with somatostatin analogues.

A patient-reported symptom diary study of midgut NET patients undergoing lutetium Lu-177 dotatate, published in Cancers, also found that patients recorded improvements in gastrointestinal symptoms across their treatment cycles. These findings suggest that PRRT may offer a dual benefit in functional NETs: slowing tumour growth and reducing the hormone load that drives carcinoid symptoms.

How Much Symptom Relief Can You Expect - and When?

The honest answer is that results vary. Not every patient with functional NETs and carcinoid syndrome will experience the same degree of improvement.

Some patients report fewer or milder flushing episodes after the first one or two cycles. Others notice a gradual reduction in diarrhea frequency over several months as tumour burden decreases. A smaller group may not see meaningful hormone-symptom relief even if PRRT is slowing tumour growth.

Several factors may influence how much symptom relief you experience:

  • The total tumour volume and extent of cancer spread to the liver - a larger hormone-producing tumour burden means more circulating serotonin
  • How strongly somatostatin receptors are expressed on your tumour cells - shown by your Ga-68 DOTATATE PET scan result
  • Whether you continue your SSA alongside PRRT - most patients do, and this combination is standard practice
  • Your starting symptom severity and how long symptoms have been poorly controlled

Your care team will typically continue your SSA therapy during PRRT cycles to help maintain hormone control while the radioactive treatment takes effect. The dose or timing of your SSA may be adjusted around each PRRT infusion date.

A Note on Carcinoid Crisis During PRRT

Patients with active carcinoid syndrome carry a small risk of carcinoid crisis during any medical procedure - including a PRRT infusion. A carcinoid crisis is a sudden, severe release of hormones that can cause a dangerous drop in blood pressure, intense flushing, bronchospasm, and rapid heart rate. It is uncommon but serious.

PRRT centers prevent carcinoid crisis by giving octreotide before the lutetium Lu-177 dotatate infusion and monitoring patients closely during and after the procedure. This is one reason where you receive PRRT matters for patients with active carcinoid syndrome.

If you are considering travelling for PRRT because it is not available in your country, you can have your scans reviewed by the Art of Healing Cancer team before booking travel. They can assess your DOTATATE-PET results and help determine if you are eligible for PRRT and how to manage your care during treatment.

What Makes You Eligible for PRRT When You Have Carcinoid Syndrome?

The core eligibility requirement for lutetium Lu-177 dotatate is the same whether or not your NET is functional. Your tumour must show sufficient somatostatin receptor expression on a Ga-68 DOTATATE PET scan. This means the scan confirms the tracer binds strongly to your tumour cells - which predicts that the radioactive treatment will reach them effectively.

Our page on how Ga-68 DOTATATE PET determines your PRRT eligibility explains how scan results are interpreted and what different uptake levels mean for your candidacy.

Other factors your oncologist will review include your kidney function, bone marrow reserve, and liver function. Because lutetium Lu-177 dotatate passes through the kidneys as it leaves the body, kidney health is monitored before and after every cycle. Tumour grade also matters - your pathology grade (expressed as a Ki-67 index) helps determine whether PRRT is right for your tumour at this stage. You can explore this further on our page about what your NET pathology grade means for PRRT eligibility.

Managing Daily Symptoms While You Wait for PRRT to Take Effect

The time between eligibility evaluation and the start of PRRT - and during the early cycles - can be demanding when you are living with active carcinoid syndrome. Flushing episodes are often unpredictable. Nighttime diarrhea can repeatedly disrupt sleep, compounding fatigue and making recovery between cycles harder.

Alongside your medical treatment, some patients find practical benefit in adjusting meal timing, limiting foods that are known to trigger flushing (such as spicy foods, alcohol, and aged cheeses), and working with a dietitian who has experience with NET patients. Nocturnal diarrhea and night sweats from flushing often disrupt sleep, a major quality-of-life issue in carcinoid syndrome. If you are looking for over-the-counter support during this period, you may find sleep support helpful from Ayurnomics - discuss any supplements with your care team before starting.

Your oncologist may also adjust your SSA dose in the weeks before your first PRRT cycle to try to stabilise hormone output as much as possible going into treatment.

When to Talk to Your Doctor

Speak with your oncologist if your carcinoid syndrome symptoms - flushing, diarrhea, abdominal cramping, or wheezing - are becoming harder to control on your current medication. Ask specifically whether PRRT has been considered for your case and whether a Ga-68 DOTATATE PET scan has been done or is needed to assess your eligibility.

If you would like a review of whether lutetium Lu-177 dotatate may fit your situation, you can contact Lutetium Therapy to have your scans and pathology report assessed for eligibility. If PRRT is not suitable for you, they can discuss other treatment options with you.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Does PRRT eliminate carcinoid syndrome symptoms completely?

Not always. Some patients see a significant reduction in flushing and diarrhea. Others notice gradual improvement over several cycles as tumour burden decreases. A smaller group may have limited hormone-symptom relief even if PRRT is slowing tumour growth. Response depends on how much of the tumour burden is producing hormones, your somatostatin receptor expression levels, and individual factors your oncologist can discuss with you.

Will I still need to take my SSA (octreotide or lanreotide) during PRRT?

For most patients with active carcinoid syndrome, yes. Your oncologist will typically continue your somatostatin analogue therapy during PRRT cycles. The SSA helps maintain hormone control while the radioactive treatment takes effect. Your dose or timing may be adjusted around each infusion date to reduce the risk of carcinoid crisis.

How soon after starting PRRT might I notice symptom improvement?

Some patients report fewer or milder flushing episodes after the first one or two cycles. Others see gradual improvement over several months as tumour burden reduces. Your care team will monitor your symptoms and relevant markers at each visit to track how well treatment is working.

What is carcinoid crisis and how is it prevented during PRRT?

Carcinoid crisis is a sudden, severe release of hormones from the tumour that can cause dangerously low blood pressure, intense flushing, bronchospasm, and a rapid heart rate. In patients with active carcinoid syndrome, experienced PRRT centres take preventive steps before each infusion - typically including a pre-treatment dose of octreotide and close monitoring throughout the procedure. It is important to choose a centre that is familiar with managing functional NETs.

Can I receive PRRT if my carcinoid syndrome is not yet well controlled?

Active, difficult-to-control carcinoid syndrome requires careful planning before PRRT. Your care team will aim to stabilise your symptoms as much as possible before starting treatment, often by adjusting your SSA therapy. PRRT itself may then contribute to longer-term hormone control as tumour cells are reduced. This is a decision made on a case-by-case basis with your oncology team.

Does PRRT work for carcinoid syndrome in pancreatic NETs as well as midgut NETs?

Most of the evidence for PRRT and carcinoid syndrome comes from midgut NET patients, who are most likely to have serotonin-producing functional tumours. Pancreatic NETs can produce different hormones - such as insulin, glucagon, gastrin, or VIP - causing different syndromes. PRRT may still be considered for pancreatic NETs if somatostatin receptor expression is confirmed on imaging, but the hormone-control data differs from the midgut experience. Discuss your specific tumour type and functional syndrome with a specialist in neuroendocrine tumour care.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

PRRT for Carcinoid Syndrome in Functional GEP-NETs | lutetium-therapy